(133 days)
Not Found
No
The device description and performance studies focus on the chemical composition, delivery system, and physical effects of the vapocoolant, with no mention of AI or ML technologies.
Yes
The device is intended to lessen pain associated with injections and provide temporary relief for minor sports injuries, classifying it as a therapeutic device.
No
The Vapocoolshot Mist is intended for topical application to the skin and mucous membranes to minimize cooling areas for lessening pain and temporary relief of minor injuries. It achieves this through rapid evaporation of non-medicated propellants for a transient refrigerant action. It does not analyze any physiological parameters or provide any diagnostic information.
No
The device description clearly states it is a canister with an accessory nozzle that delivers a chemical mist, indicating it is a physical hardware device, not software.
Based on the provided information, this device is not an IVD (In Vitro Diagnostic).
Here's why:
- Intended Use: The intended use is for topical application to skin and mucous membranes to provide temporary pain relief through cooling. This is a physical effect on the body's surface.
- Device Description: The device is a vapocoolant canister that delivers a mist of refrigerants. It works by rapidly cooling the skin through evaporation.
- Lack of Diagnostic Purpose: There is no mention of the device being used to diagnose a disease or condition, or to examine specimens taken from the human body. IVDs are specifically designed for these purposes.
The device is a therapeutic device that provides temporary pain relief through a physical mechanism (cooling). It does not perform any in vitro diagnostic testing.
N/A
Intended Use / Indications for Use
The Vapocoolshot Mist is intended for topical application to skin, intact mucous membrane (oral cavity, nasal passageways, lips) and minor open wounds. The Vapocoolshot Mist is used to target and minimize cooling area for lessening pain associated with injections (venipuncture, IV starts, cosmetic procedures (such as lancing boils, incision, drainage of small abscesses and sutures) and the temporary relief of minor sports injuries (sprains, bruising, cuts, and abrasions).
Product codes
MLY
Device Description
The Vapocoolshot Mist is a Vapocoolant (skin refrigerant) canister with an accessory nozzle that is intended for instant topical anesthetic. The Vapocoolshot Mist allows for the ease of use for a rapid, targeted, comfortable misting action of the refrigerant (cold like ice) onto the skin surface.
Vapocoolshot Mist is prescription device designed to deliver a standard mixture 245fa (1,1,3,3-Pentafluoropropane) and 134a (1,1,1,2-Tetrafluoroethane) mist spray that will provide a transient refrigerant action. This mixture self-propels itself from the delivery system, which is designed to account for its low vapor pressure. The Vapocoolshot's nozzle, device's delivery system, controls the amount of the vapocoolant mixture that is dispensed. The mist spray configuration produces very fine droplets that create cooling at the points of contact. The Vapocoolshot produces a mist that contacts the skin surface at a targeted location. The skin is cooled through rapid evaporation of the non-medicated propellants.
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
skin, intact mucous membrane (oral cavity, nasal passageways, lips) and minor open wounds.
Indicated Patient Age Range
Not Found
Intended User / Care Setting
Not Found
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)
Biocompatibility: The subject device has Indirect Contact. The gas blend is approved for this clinical use, application and methodology. The materials are compatible.
Chemical Composition Confirmation: The subject device, Primary predicate and Predicate 1 are composed of identical aerosols profiles, which is 245fa (1,1,1,3,3-Pentafluoropropane) at 95% of the total and 134a (1,1,1,2-Tetrafluoroethane) at 5% of the total mixture. The subject device's aerosol is checked and verified upon receipt from the aerosol supplier to ensure the same chemical profile as the Primary predicate (Gebauer).
Structural and Parts Composition: Engineering verification measurements were taken, and visual inspections were made to determine the Vapocoolashot Mist canisters, valves, and caps were equivalent to the Primary predicate (Gebauer). Engineering verification measurements were taken, and visual inspections were made to determine the Vapocoolshot was equivalent to the Predicate 1(Ouchless).
Directions for Use (Clinical Use) Application and Methodology: All key elements of the Directions for Use (DFU) between the Primary predicate (Gebauer), Predicate 1 and the subject device are similar, intended use, precaution statements, warning statements, and contraindication statements, and treatment regimen. No significant differences exist between the Predicate 1 (Ouchless) and subject device's Directions for Use.
Side-by-Side Temperature & Output Bench Testing: Tests were selected and performed to ensure the subject device's output performances are similar as a whole with its Primary Predicate (Gebauer). Comparative performance testing was conducted as it related to temperature output at the application surface and volume dispensed per actuation/total and equivalent results were demonstrated.
Stability Protocol and Shelf Life Testing: A stability protocol was developed to ensure that the identity, strength, quality, and purity of the product are maintained throughout its labeled dating period. Testing assessments were conducted under controlled conditions at room temperature and under accelerated conditions. All requirements were confirmed to meet established acceptance criteria.
Summary: Based on the performance evaluations conducted, Vapocoolshot Mist was found to be safe and effective to the Primary predicate (Gebauer).
Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)
Not Found
Predicate Device(s)
Reference Device(s)
Not Found
Predetermined Change Control Plan (PCCP) - All Relevant Information
Not Found
N/A
0
Image /page/0/Picture/0 description: The image contains the logo of the U.S. Food and Drug Administration (FDA). On the left is the Department of Health & Human Services logo. To the right of that is the FDA logo, which is a blue square with the letters "FDA" in white. To the right of the blue square is the text "U.S. FOOD & DRUG ADMINISTRATION" in blue.
April 14, 2020
Vapocoolshot, Inc. % Neil Ross Chief Scientific Officer, Quality Affairs N2Pharma, LLC 1071 Nandina Dr Weston, Florida 33327
Re: K193349
Trade/Device Name: Vapocoolshot Mist Regulatory Class: Unclassified Product Code: MLY Dated: October 11, 2019 Received: December 3, 2019
Dear Neil Ross:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. Although this letter refers to your product as a device, please be aware that some cleared products may instead be combination products. The 510(k) Premarket Notification Database located at https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm identifies combination product submissions. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting of medical device-related adverse events) (21 CFR 803) for
1
devices or postmarketing safety reporting (21 CFR 4, Subpart B) for combination products (see https://www.fda.gov/combination-products/guidance-regulatory-information/postmarketing-safety-reportingcombination-products); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820) for devices or current good manufacturing practices (21 CFR 4, Subpart A) for combination products; and, if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to https://www.fda.gov/medical-device-safety/medical-device-reportingmdr-how-report-medical-device-problems.
For comprehensive regulatory information about mediation-emitting products, including information about labeling regulations, please see Device Advice (https://www.fda.gov/medicaldevices/device-advice-comprehensive-regulatory-assistance) and CDRH Learn (https://www.fda.gov/training-and-continuing-education/cdrh-learn). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (https://www.fda.gov/medical-device-advice-comprehensive-regulatoryassistance/contact-us-division-industry-and-consumer-education-dice) for more information or contact DICE by email (DICE@fda.hhs.gov) or phone (1-800-638-2041 or 301-796-7100).
Sincerely,
For Vivek Pinto, PhD Director DHT5B: Division of Neuromodulation and Physical Medicine Devices OHT5: Office of Neurological and Physical Medicine Devices Office of Product Evaluation and Quality Center for Devices and Radiological Health
Enclosure
2
Indications for Use
510(k) Number (if known)
Device Name Vapocoolshot Mist
Indications for Use (Describe)
The Vapocoolshot Mist is intended for topical application to skin, intact mucous membrane (oral cavity, nasal passageways, lips) and minor open wounds. The Vapocoolshot Mist is used to target and minimize cooling area for lessening pain associated with injections (venipuncture, IV starts, cosmetic procedures (such as lancing boils, incision, drainage of small abscesses and sutures) and the temporary relief of minor sports injuries (sprains, bruising, cuts, and abrasions).
| Type of Use (Select one or both, as applicable) | |
|---|---|
| ☒ Prescription Use (Part 21 CFR 801 Subpart D) | ☐ Over-The-Counter Use (21 CFR 801 Subpart C) |
CONTINUE ON A SEPARATE PAGE IF NEEDED.
This section applies only to requirements of the Paperwork Reduction Act of 1995.
DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.
The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:
Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff(@fda.hhs.gov
"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."
3
K193349 – 510(k) Summary
Vapocoolshot Inc. – Vapocoolshot Mist
I. SUBMITTER
| Owner: | Vapocoolshot Inc.
1155 Main Street, Suite 105
Jupiter FL, 33458
(561) 427-0420 (o)
(561) 420-8330 (fax) |
|--------------------------------|---------------------------------------------------------------------------------------------------------------------|
| Contact Person: | Jacob Leibovici
1155 Main Street, Suite 105
Jupiter FL, 33458
(561) 306-3434 (m)
(561) 427-0420 (o) |
| Date Prepared: | February 28, 2020 |
| Subject Device: | |
| Trade/Device Name: | Vapocoolshot Mist (Model VM11000) |
| Common Name: | Refrigerant, Topical (Vapocoolant) |
| Review panel:
Product code: | Physical Medicine
MLY |
| Primary Predicate Device: | Gebauer's Pain Ease (Mist Spray & Stream Spray)
Gebauer Company.
K172028
Legally marketed medical device |
| Predicate 1: | Ouchless
Occam Design LLC
K093951 |
4
II. DEVICE DESCRIPTION
The Vapocoolshot Mist is a Vapocoolant (skin refrigerant) canister with an accessory nozzle that is intended for instant topical anesthetic. The Vapocoolshot Mist allows for the ease of use for a rapid, targeted, comfortable misting action of the refrigerant (cold like ice) onto the skin surface.
Vapocoolshot Mist is prescription device designed to deliver a standard mixture 245fa (1,1,3,3-Pentafluoropropane) and 134a (1,1,1,2-Tetrafluoroethane) mist spray that will provide a transient refrigerant action. This mixture self-propels itself from the delivery system, which is designed to account for its low vapor pressure. The Vapocoolshot's nozzle, device's delivery system, controls the amount of the vapocoolant mixture that is dispensed. The mist spray configuration produces very fine droplets that create cooling at the points of contact. The Vapocoolshot produces a mist that contacts the skin surface at a targeted location. The skin is cooled through rapid evaporation of the non-medicated propellants.
Vapocoolshot Mist canister is equivalent to the Primary predicate device. Gebauer's Pain Ease. Both devices are indicated for topical application to skin, intact mucous membrane (oral cavity, nasal passageways, lips) and minor open wounds. The Vapocoolshot Mist is used to target and minimize cooling area for lessening pain associated with injections (venipuncture, IV starts, cosmetic procedures), minor surgical procedures (such as lancing boils, incision, drainage of small abscesses and sutures) and the temporary relief of minor sports injuries (sprains, bruising, cuts, and abrasions).
Vapocoolshot Mist is equivalent to the Predicate 1, Ouchless. Both Vapocoolshot and Ouchless devices are indicated for topical application of refrigerant (cold like ice) to the skin and both devices have the same exact mixture blend of vapocoolant.
III. INDICATIONS FOR USE
The Vapocoolshot Mist is intended for topical application to skin, intact mucous membrane (oral cavity, nasal passageways, lips) and minor open wounds. The Vapocoolshot Mist is used to target and minimize cooling area for lessening pain associated with injections (venipuncture, IV starts, cosmetic procedures), minor surgical procedures (such as lancing boils, incision, drainage of small abscesses and sutures) and the temporary relief of minor sports injuries (sprains, bruising, cuts, and abrasions).
IV. COMPARISON OF TECHNOLOGICAL CHARACTERISTICS WITH THE PREDICATE DEVICES
The subject device Vapocoolshot Mist has similar technical characteristics as the Primary predicate device (Gebauer), including materials, design, and energy source. Refer to the following table for the comparison between the subject device Vapocoolshot Mist and the Primary predicate:
| Comparison Chart – Technological Characteristics | ||
|---|---|---|
| Trade Name | Vapocoolshot Mist | |
| K193349 | ||
| Subject Device | Gebauer's Pain Ease | |
| K172028 | ||
| Primary Predicate |
5
| Type | Rx | Rx | Comparison Chart – Technological Characteristics | ||
|---|---|---|---|---|---|
| Product Design | Pressurized dispensing container, which | ||||
| includes the vapocoolant, canister, | |||||
| valve, actuator, cap and an accessory | |||||
| nozzle. | Pressurized dispensing container, which | ||||
| includes the vapocoolant, canister, | |||||
| valve, actuator, and cap. | Trade Name | Vapocoolshot | |||
| K193349 | |||||
| Subject Device | Ouchless | ||||
| K093951 | |||||
| Predicate 1 | |||||
| Indication for Use | The Vapocoolashot Mist is intended for topical application to skin, intact | ||||
| mucous membrane (oral cavity, nasal | |||||
| passageways, lips) and minor open | |||||
| wounds. The Vapocoolshot Mist is used | |||||
| to target and minimize cooling area for | |||||
| lessening pain associated with | |||||
| injections (venipuncture, IV starts, | |||||
| cosmetic procedures), minor surgical | |||||
| procedures (such as lancing boils, | |||||
| incision, drainage of small abscesses | |||||
| and sutures) and the temporary relief of | |||||
| minor sports injuries (sprains, bruising, | |||||
| cuts, and abrasions). | The vapocoolant (skin refrigerant) is | ||||
| intended for topical application to skin, | |||||
| intact mucous membrane (oral cavity, nasal | |||||
| passageways, lips) and minor open wounds. | |||||
| The Vapocoolshot Mist can control pain | |||||
| associated with injections | |||||
| (venipuncture, IV starts, cosmetic | |||||
| procedures), minor surgical procedures (such | |||||
| as lancing boils, incision, drainage of | |||||
| small abscesses and sutures) and the | |||||
| temporary relief of minor sports injuries | |||||
| (sprains, bruising, cuts, and abrasions). | Type | Rx | Rx | ||
| Product Fill Volume | 2oz (65 mL) | 3.5oz (103.5mL) | Product Design | Pressurized dispensing container, which | |
| includes the vapocoolant, canister, valve, | |||||
| actuator, cap and accessory nozzle. | Pressurized dispensing container, which | ||||
| includes the vapocoolant, canister, valve, and | |||||
| push button. (No canister cap, No actuator) | |||||
| Vapocoolant | |||||
| Composition | 1,1,1,3,3- | ||||
| Pentafluoropropane (HFC-245fa) 95% | |||||
| and | |||||
| 1,1,1,2-Tetrafluoroethane (HFC-134a) | |||||
| 5% | 1,1,1,3,3- | ||||
| Pentafluoropropane (HFC-245fa) 95% and | |||||
| 1,1,1,2- | |||||
| Tetrafluoroethane (HFC-134a) 5% | Indication for | ||||
| Use | The Vapocoolashot Mist is intended for topical | ||||
| application to skin, intact mucous membrane | |||||
| (oral cavity, nasal passageways, lips) and minor | |||||
| open wounds. The Vapocoolshot Mist is used to | |||||
| target and minimize cooling area for lessening | |||||
| pain associated with injections (venipuncture, | |||||
| IV starts, cosmetic procedures), minor surgical | |||||
| procedures (such as lancing boils, incision, | |||||
| drainage of small abscesses and sutures) and the | |||||
| temporary relief of minor sports injuries | |||||
| (sprains, bruising, cuts, and abrasions). | Used like ice for the temporary relief of | ||||
| minor pain. | |||||
| Energy Delivered | Thermal Energy via Refrigerant Spray | Thermal Energy via Refrigerant Spray | Product Fill | ||
| Volume | 2oz (65 mL) | 19mL | |||
| Energy Deposited | N/A | N/A | Vapocoolant | ||
| Composition | 1,1,1,3,3- | ||||
| Pentafluoropropane (HFC-245fa) 95% | |||||
| and | |||||
| 1,1,1,2-Tetrafluoroethane (HFC-134a) 5% | 1,1,1,3,3- Pentafluoropropane (HFC-245fa) | ||||
| 95% | |||||
| and | |||||
| 1,1,1,2-Tetrafluoroethane (HFC-134a) 5% | |||||
| Vapocoolant Discharge | |||||
| Method | Depress the Actuator Button to release | ||||
| the vapocoolant | Depress the Actuator Button to release the | ||||
| vapocoolant | Energy | ||||
| Delivered | Thermal Energy via Refrigerant Spray | Thermal Energy via Refrigerant Spray | |||
| Environmental | |||||
| Compatibility | Non-Flammable | Non-Flammable | Energy | ||
| Deposited | N/A | N/A | |||
| Mechanical Safety | Mechanism has positive shut-off | ||||
| release. | Mechanism has positive shut-off release | Vapocoolant | |||
| Discharge | |||||
| Method | Depress the Actuator Button to release the | ||||
| vapocoolant | Depress the Button to release the | ||||
| vapocoolant | |||||
| Environmental | |||||
| Compatibility | Non-Flammable | Non-Flammable | |||
| Mechanical | |||||
| Safety | Mechanism has positive shut-off release. | Mechanism has positive shut- off release |
The Vapocoolshot Mist device has similar technical and technological characteristics as the Predicate 1 (Ouchless), including materials, design, and energy source. Refer to the following table for the comparison between the Vapocoolshot Mist device and the Predicate 1:
6
Equivalence:
The Primary predicate (Gebauer) is legally marketed device. The subject device as a unit has similar intended use as the Primary predicate device.
7
The subject device is a prescription device as well as Primary predicate and Predicate 1.
The subject device has the same technological characteristics as the Predicate 1(Ouchless). There are no technological differences, including no changes in the materials, design, energy source, or other features of the device from those of the Predicate 1.
The subject, Primary predicate, and Predicate 1 devices use identical (substantially equivalent) chemical composition by type and percent of components: 245fa (1,1,1,3,3-Pentafluoropropane) at 95% of the total and 134a (1,1,2-Tetrafluoroethane) at 5% of the total mixture.
Labeling:
The labeling of subject device has been prepared to ensure the medical professional has adequate and clear instructions for safety and usage. The canister labeling, directions for use, safety and warning statements relating to the Vapocoolant Mist are equivalent to the Primary predicate (Gebauer) and Predicate 1(Ouchless).
V. PERFORMANCE DATA.
Biocompatibility
The subject device has Indirect Contact. The gas blend is approved for this clinical use, application and methodology. The materials are compatible.
Chemical Composition Confirmation
The subject device, Primary predicate and Predicate 1 are composed of identical aerosols profiles, which is 245fa (1,1,1,3,3-Pentafluoropropane) at 95% of the total and 134a (1,1,1,2-Tetrafluoroethane) at 5% of the total mixture.
The subject device's aerosol is checked and verified upon receipt from the aerosol supplier to ensure the same chemical profile as the Primary predicate (Gebauer).
Structural and Parts Composition
Engineering verification measurements were taken, and visual inspections were made to determine the Vapocoolashot Mist canisters, valves, and caps were equivalent to the Primary predicate (Gebauer).
Engineering verification measurements were taken, and visual inspections were made to determine the Vapocoolshot was equivalent to the Predicate 1(Ouchless).
Directions for Use (Clinical Use) Application and Methodology:
All key elements of the Directions for Use (DFU) between the Primary predicate (Gebauer), Predicate 1 and the subject device are similar, intended use, precaution statements, warning statements, and contraindication statements, and treatment regimen. No significant differences exist between the Predicate 1 (Ouchless) and subject device's Directions for
8
Use.
Side-by-Side Temperature & Output Bench Testing
Tests were selected and performed to ensure the subject device's output performances are similar as a whole with its Primary Predicate (Gebauer).
Comparative performance testing was conducted as it related to temperature output at the application surface and volume dispensed per actuation/total and equivalent results were demonstrated.
Stability Protocol and Shelf Life Testing
A stability protocol was developed to ensure that the identity, strength, quality, and purity of the product are maintained throughout its labeled dating period. Testing assessments were conducted under controlled conditions at room temperature and under accelerated conditions. All requirements were confirmed to meet established acceptance criteria.
Summary
Based on the performance evaluations conducted, Vapocoolshot Mist was found to be safe and effective to the Primary predicate (Gebauer).
VI. CONCLUSION
Based on the information provided in the submission, it is concluded that the Vapocoolshot Mist is safe and effective for its intended use and has demonstrated similar to the Primary predicated (Gebauer). The Vapocoolshot as a unit does not raise additional questions of safety, efficacy and effectiveness different from the Predicate 1 (Ouchless).